Daniel Dever is a Research Instructor in the Laboratory of Dr. Matthew Porteus at Stanford University. He completed his PhD in molecular toxicology at the University of Rochester where he studied the mechanisms of the aryl hydrocarbon receptor in mediating cerebellar transcriptional programs. During his postdoctoral work in the Porteus group, he (with others) developed a CRISPR/Cas9-based beta-globin (HBB) gene editing by homologous recombination methodology (previously known as gene targeting) in CD34+ hematopoietic stem and progenitor cells (HSPCs) as a potential therapeutic strategy to treat severe sickle cell disease. Details of these studies are described in our article in Nature (Dever et al., 2016). He is now leading IND-enabling preclinical efficacy, feasibility, safety and tumorgenicity studies for FDA approval of a first-in-human clinical trial at Stanford for the treatment of severe sickle cell disease using CRISPR/Cas9-based HBB gene correction.